The definition of neuronopathic Gaucher disease
Raphael Schiffmann(Texas Christian University), Ari Zimran(Hebrew University of Jerusalem), Ellen Sidransky(National Institutes of Health), Elin Haf Davies(AM Technology (United Kingdom)), Han‐Wook Yoo(CHA University Bundang Medical Center), Shoshana Revel‐Vilk(Hebrew University of Jerusalem), Jeff Szer(The Royal Melbourne Hospital), Uma Ramaswami(The Royal Free Hospital), Aya Narita(Tottori University), Ashok Vellodi(Great Ormond Street Hospital), Elena Lukina(National Medical Research Center for Hematology), Tanya Collin‐Histed(Health Alliance International), Michael P. Wajnrajch(Pfizer (United States)), David Arkadir(Hadassah Medical Center), Eugen Mengel(University of Hohenheim), Özlem Göker-Alpan(Lysosomal and Rare Disorders Research and Treatment Center), Aimée Donald(University of Manchester), Arndt Rolfs(Population Health Research Institute), Jeff Sevigny(Ovid Therapeutics (United States)), Magy Abdelwahab(Cairo University), Tama Dinur(Shaare Zedek Medical Center)
Cited by 102
Related Papers
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|2006|1.3k
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
|New England Journal of Medicine|2020|859
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria
|Blood|2007|578
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
|New England Journal of Medicine|2016|555
One million haemopoietic stem-cell transplants: a retrospective observational study
|The Lancet Haematology|2015|434